Xenon Pharmaceuticals Inc.

Contributing Author

Recent Articles by Xenon Pharmaceuticals Inc.

Mar-12	Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares XENE GlobeNewswire
Mar-10	Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering XENE GlobeNewswire
Mar-09	Xenon Pharmaceuticals Announces Proposed Public Offering XENE +49.64% GlobeNewswire
Mar-09	Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) XENE +49.64% GlobeNewswire
Mar-08	Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 XENE GlobeNewswire
Feb-26	Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update XENE GlobeNewswire
Jan-16	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Jan-12	Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference XENE GlobeNewswire
Jan-05	Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference XENE -6.07% GlobeNewswire
Dec-05	Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 XENE GlobeNewswire
Dec-04	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Dec-03	Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 XENE GlobeNewswire
Nov-25	Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 XENE GlobeNewswire
Nov-06	Xenon to Present at Upcoming Investor Conferences XENE GlobeNewswire
Nov-03	Xenon Reports Third Quarter 2025 Financial Results & Business Update XENE GlobeNewswire
Oct-27	Xenon to Report Q3 2025 Financial Results on November 3, 2025 XENE GlobeNewswire
Oct-16	Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer XENE GlobeNewswire
Oct-07	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Sep-25	Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain XENE GlobeNewswire
Aug-29	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Aug-11	Xenon Reports Second Quarter 2025 Financial Results & Business Update XENE +5.51% XENE GlobeNewswire
Aug-04	Xenon to Report Q2 2025 Financial Results on August 11, 2025 XENE +8.72% GlobeNewswire
Aug-01	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Jun-27	Xenon Joins the Russell 3000 and Russell 2000 Indexes XENE GlobeNewswire
Jun-26	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Jun-24	Xenon Announces Appointment of Darren Cline as Chief Commercial Officer XENE GlobeNewswire
Jun-03	Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference XENE GlobeNewswire
May-30	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
May-14	Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference XENE GlobeNewswire
May-12	Xenon Reports First Quarter 2025 Financial Results and Provides Business Update XENE -17.43% XENE GlobeNewswire
May-05	Xenon to Report Q1 2025 Financial Results on May 12, 2025 XENE -6.29% XENE GlobeNewswire
May-02	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire

Xenon Pharmaceuticals Inc.

Recent Articles by Xenon Pharmaceuticals Inc.

Upgrade your Finviz experience